{"entity":{"id":"ascentage-pharma","kind":"company","name":"Ascentage Pharma","aka":["Ascentage Pharma Group Inc.","亚盛医药"],"tldr":"Ascentage is a Chinese biotechnology company built on protein-protein interaction inhibitors: olverembatinib, a third-generation BCR-ABL inhibitor approved in China for T315I-mutant chronic myeloid leukaemia, and the BCL-2 inhibitor lisaftoclax.","summary":"Ascentage Pharma, based in Suzhou and listed in Hong Kong and, since 2025, on Nasdaq, designs small molecules that block protein-protein interactions in apoptosis and other pathways. Olverembatinib (HQP1351), a BCR-ABL inhibitor active against the T315I mutation, was approved in China in 2021 for resistant chronic myeloid leukaemia and is in global trials with Takeda. Lisaftoclax (APG-2575) is a BCL-2 inhibitor in phase 3 trials in chronic lymphocytic leukaemia and other blood cancers. OnCo records it as a registry sponsor of phase 3 cancer trials.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.ascentage.com"},{"label":"ClinicalTrials.gov: trials led by Ascentage Pharma","url":"https://clinicaltrials.gov/search?lead=Ascentage%20Pharma"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Ascentage_Pharma"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["cml","cll","aml"],"sections":["targeted-therapy"],"technologies":[],"targets":["bcr-abl","bcl2"],"drugs":["olverembatinib"],"companies":["takeda"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04501120","nct03611868","nct05701306","nct04785196","nct04494503","nct04496349","nct06389292","nct05147467"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Suzhou","country":"CN","companyType":"biotech","website":"https://www.ascentage.com","stage":"public","investors":[],"funding":[]},"route":"/companies/ascentage-pharma/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"},{"id":"cml","kind":"cancer","name":"Chronic myeloid leukaemia (CML)","route":"/cancers/cml/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"target":[{"id":"bcl2","kind":"target","name":"BCL-2","route":"/targets/bcl2/"},{"id":"bcr-abl","kind":"target","name":"BCR::ABL1 (Philadelphia chromosome)","route":"/targets/bcr-abl/"}],"drug":[{"id":"olverembatinib","kind":"drug","name":"Olverembatinib","route":"/drugs/olverembatinib/"}],"company":[{"id":"takeda","kind":"company","name":"Takeda","route":"/companies/takeda/"}],"trial":[{"id":"nct06389292","kind":"trial","name":"A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia","route":"/trials/nct06389292/"},{"id":"nct04496349","kind":"trial","name":"A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL","route":"/trials/nct04496349/"},{"id":"nct03611868","kind":"trial","name":"A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors","route":"/trials/nct03611868/"},{"id":"nct06051409","kind":"trial","name":"A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)","route":"/trials/nct06051409/"},{"id":"nct06640361","kind":"trial","name":"A Study of Olverembatinib in SDH-deficient GIST.","route":"/trials/nct06640361/"},{"id":"nct05701306","kind":"trial","name":"APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors","route":"/trials/nct05701306/"},{"id":"nct04785196","kind":"trial","name":"APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors","route":"/trials/nct04785196/"},{"id":"nct05147467","kind":"trial","name":"Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL","route":"/trials/nct05147467/"},{"id":"nct04494503","kind":"trial","name":"Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL","route":"/trials/nct04494503/"},{"id":"nct04501120","kind":"trial","name":"Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML","route":"/trials/nct04501120/"},{"id":"nct06423911","kind":"trial","name":"Study of Olverembatinib (HQP1351) in Patients With CML-CP","route":"/trials/nct06423911/"}]}}